Translational study with genomic profiling of HER2-amplified breast cancers showed that there was significantly more enrichment of mutations known to activate RAS-MAPK signaling in metastatic cancers than in primary cancers (78). Here, ERBB2 is linked to metastatic malignant neoplasm.